Ramosetron vs ondansetron for the prevention of postoperative vomiting in children receiving fentanyl as PCA following orthopaedic surgery

Trial Profile

Ramosetron vs ondansetron for the prevention of postoperative vomiting in children receiving fentanyl as PCA following orthopaedic surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2013

At a glance

  • Drugs Ondansetron (Primary) ; Ramosetron (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top